Palantir
PLTR
195.37
+1.22
+0.63%
Palantir
US · PLTR
#35 by market cap
Listed 2020
195.37
+1.22
+0.63%
Live - 5344 symbols - heartbeat 2s ago
· 2026-10-20 10:50
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 200.86, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +56.18% YoY
Margins
- Gross margin
- 82.37%
- Operating margin
- 31.60%
- Net margin
- 36.31%
Key ratios & quality
- Altman Z-Scorei
- 200.86
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 595.41M | 742.56M | 1.09B | 1.54B | 1.91B | 2.23B | 2.87B | 4.48B |
| Gross profit | 430.01M | 500.18M | 740.13M | 1.20B | 1.50B | 1.79B | 2.30B | 3.69B |
| Selling & admin expenses | 768.00M | 771.06M | 1.35B | 1.23B | 1.30B | 1.27B | 1.48B | 1.71B |
| Research & development | 285.45M | 305.56M | 560.66M | 387.49M | 359.68M | 404.62M | 507.88M | 557.68M |
| Operating profit | -623.44M | -576.44M | -1.17B | -411.05M | -161.20M | 119.97M | 310.40M | 1.41B |
| Pretax profit | -570.93M | -567.27M | -1.18B | -488.49M | -361.03M | 237.09M | 489.17M | 1.66B |
| Tax | 9.10M | 12.38M | -12.64M | 31.89M | 10.07M | 19.72M | 21.26M | 22.72M |
| Net profit | -580.03M | -579.65M | -1.17B | -520.38M | -371.09M | 217.38M | 467.92M | 1.63B |
| Basic EPS | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 1 |
| Diluted EPS | -0.27 | -0.26 | -1.20 | -0.27 | -0.18 | 0.09 | 0.19 | 0.63 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 883.86M | 1.00B | 1.18B | 1.41B | 1.63B | 1.94B |
| Gross profit | 710.89M | 810.76M | 973.79M | 1.19B | 1.42B | 1.64B |
| Selling & admin expenses | 399.95M | 406.40M | 436.34M | 471.89M | 501.81M | 534.08M |
| Research & development | 134.89M | 135.04M | 144.19M | 143.55M | 160.98M | 192.51M |
| Operating profit | 176.05M | 269.32M | 393.26M | 575.39M | 754.00M | 912.00M |
| Pretax profit | 223.32M | 332.17M | 480.50M | 621.38M | 888.60M | 1.08B |
| Tax | 5.60M | 3.60M | 3.75M | 9.78M | 12.20M | 15.38M |
| Net profit | 217.72M | 328.57M | 476.75M | 611.61M | 876.40M | 1.07B |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.08 | 0.13 | 0.18 | 0.24 | 0.34 | 0.41 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.22B | 1.21B | 2.26B | 2.86B | 3.04B | 4.14B | 5.93B | 8.36B |
| Cash & ST investments | 1.12B | 1.08B | 2.01B | 2.52B | 2.63B | 3.67B | 5.23B | 7.18B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.43B | 1.59B | 2.69B | 3.25B | 3.46B | 4.52B | 6.34B | 8.90B |
| Total current liabilities | 531.90M | 728.60M | 603.82M | 660.06M | 587.94M | 746.02M | 996.02M | 1.18B |
| Short-term debt | -- | -- | 29.08M | 39.93M | 45.10M | 54.18M | 43.99M | 45.86M |
| Long-term debt | -- | 396.07M | 197.98M | -- | -- | -- | -- | -- |
| Total liabilities | 3,182,393,000.00 | 3,574,667,000.00 | 1,167,954,000.00 | 956,420,000.00 | 818,802,000.00 | 961,460,000.00 | 1,246,477,000.00 | 1,412,381,000.00 |
| Total equity | -1.75B | -1.98B | 1.52B | 2.29B | 2.64B | 3.56B | 5.09B | 7.49B |
| Retained earnings | -3.23B | -3.80B | -4.97B | -5.49B | -5.86B | -5.65B | -5.19B | -3.56B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 6.28B | 6.89B | 7.59B | 8.36B | 9.55B | 11.10B |
| Cash & ST investments | 5.43B | 6.00B | 6.44B | 7.18B | 8.03B | 9.41B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 6.74B | 7.37B | 8.11B | 8.90B | 10.20B | 11.68B |
| Total current liabilities | 967.44M | 1.09B | 1.18B | 1.18B | 1.38B | 1.54B |
| Short-term debt | 44.42M | 45.47M | 46.27M | 45.86M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,217,944,000.00 | 1,340,124,000.00 | 1,425,691,000.00 | 1,412,381,000.00 | 1,642,902,000.00 | 1,793,680,000.00 |
| Total equity | 5.52B | 6.03B | 6.69B | 7.49B | 8.56B | 9.88B |
| Retained earnings | -4.97B | -4.65B | -4.17B | -3.56B | -2.69B | -1.63B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -39.01M | -165.22M | -296.61M | 333.85M | 223.74M | 712.18M | 1.15B | 2.13B |
| Depreciation & amortization | 13.91M | 12.26M | 13.87M | 14.90M | 22.52M | 33.35M | 31.59M | 26.15M |
| Free cash flow | -52.02M | -178.31M | -308.84M | 321.22M | 183.71M | 697.07M | 1.14B | 2.10B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 88.77M | 88.80M | 938.75M | -- | 0 | 0 | -64.20M | -74.99M |
| Ending cash balance | 1.27B | 1.40B | 2.13B | 2.37B | 2.63B | 850.11M | 2.12B | 1.45B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 310.26M | 539.25M | 507.66M | 777.30M | 899.17M | 1.22B |
| Depreciation & amortization | 6.62M | 6.53M | 5.98M | 7.02M | 6.77M | 8.22M |
| Free cash flow | 304.08M | 531.62M | 500.87M | 764.02M | 891.76M | 1.20B |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -18.00M | -18.60M | -19.20M | -19.20M | -- | -- |
| Ending cash balance | 1.02B | 951.23M | 1.64B | 1.45B | 2.32B | 2.06B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -27.29 | -15.39 | 6.95 | 10.90 | 26.23 |
| ROA %i | -41.80 | -38.32 | -54.45 | -17.53 | -11.14 | 5.26 | 8.51 | 21.32 |
| ROIC %i | -- | -- | -- | -22.91 | -14.38 | 2.81 | 6.12 | 21.76 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | 0.28 |
| EBIT margin %i | -95.31 | -75.98 | -106.61 | -31.45 | -18.73 | 10.81 | 10.83 | 31.60 |
| FCF / sales %i | -- | -- | -- | 20.83 | 9.64 | 31.33 | 39.83 | 46.94 |
| Current ratioi | 2.29 | 1.67 | 3.74 | 4.34 | 5.17 | 5.55 | 5.96 | 7.11 |
| Quick ratioi | 2.13 | 1.55 | 3.59 | 4.11 | 4.92 | 5.41 | 5.83 | 6.99 |
| Debt / assetsi | -- | 24.85 | 16.98 | 8.01 | 7.21 | 5.07 | 3.77 | 2.58 |
| LT debt / equityi | -- | -- | 28.10 | 9.61 | 7.96 | 5.04 | 3.90 | 2.48 |
| Interest coveragei | -164.97 | -184.32 | -82.39 | -133.20 | -87.97 | 69.33 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 37.32 | 36.92 | 26.75 | 22.95 | 32.92 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 52.59 | 125.29 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.41 | 15.30 | 19.76 | 26.23 | 32.89 | 38.42 |
| ROA %i | 9.89 | 12.16 | 15.78 | 21.32 | 26.94 | 31.68 |
| ROIC %i | 7.75 | 10.60 | 15.16 | 21.76 | 28.55 | 34.20 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 13.02 | 16.55 | 21.81 | 31.60 | 38.13 | 42.80 |
| FCF / sales %i | 42.32 | 49.66 | 46.04 | 46.94 | 51.46 | 54.55 |
| Current ratioi | 6.49 | 6.32 | 6.43 | 7.11 | 6.91 | 7.23 |
| Quick ratioi | 6.36 | 6.19 | 6.31 | 6.99 | 6.82 | 7.09 |
| Debt / assetsi | 3.63 | 3.23 | 2.90 | 2.58 | 2.08 | 1.81 |
| LT debt / equityi | 3.69 | 3.24 | 2.87 | 2.48 | 2.51 | 2.16 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Government is the largest reported line at 51.15% of revenue, across 2 reported segments.
- Commercial follows at 48.85%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Government51.15%
Commercial48.85%
Quote time 2026-10-20 10:50:16 · For reference only, not investment advice and not tailored to your situation.
either this is the most overvalued stock in the market or the early innings of something huge, and honestly the price action makes it impossible to tell which camp is right this week.